# Cancer Venous Thromboembolism (VTE)

Study · id `cardio:ct-nct02073682` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02073682](<https://clinicaltrials.gov/study/NCT02073682>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02073682

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1046 participants.

## Technical summary

Registry record NCT02073682. Randomized; no masking; primary purpose treatment. Start 2015-07-16 (actual); primary completion 2017-09-15 (actual). Results posted on 2018-10-24.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1046 participants (enrolled count; ClinicalTrials.gov record NCT02073682, source copy `cardio:ctgov-nct02073682-2019-03-06`, retrieved 2026-10-31)
- Started: 2015-07-16 (actual) (ClinicalTrials.gov record NCT02073682, source copy `cardio:ctgov-nct02073682-2019-03-06`, retrieved 2026-10-31)
- Primary completion: 2017-09-15 (actual) (ClinicalTrials.gov record NCT02073682, source copy `cardio:ctgov-nct02073682-2019-03-06`, retrieved 2026-10-31)
- Completion: 2017-09-15 (actual) (ClinicalTrials.gov record NCT02073682, source copy `cardio:ctgov-nct02073682-2019-03-06`, retrieved 2026-10-31)
- Results first posted: 2018-10-24 (ClinicalTrials.gov record NCT02073682, source copy `cardio:ctgov-nct02073682-2019-03-06`, retrieved 2026-10-31)
- Countries: United States; Belgium; France; Hungary; Italy; Netherlands (ClinicalTrials.gov record NCT02073682, source copy `cardio:ctgov-nct02073682-2019-03-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02073682-2019-03-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Cancer Venous Thromboembolism (VTE)
- Condition: Venous Thromboembolism (VTE)
- Condition: Deep Vein Thrombosis (DVT)
- Condition: Pulmonary Embolism (PE)
- Condition: Cancer
- Intervention (Drug): Edoxaban
- Intervention (Drug): Dalteparin
- Intervention (Drug): Low molecular weight heparin
- Lead sponsor: Daiichi Sankyo
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry lists this organization as the lead sponsor: Daiichi Sankyo (`cardio:org-daiichi-sankyo`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism (`cardio:pubmed-29231094`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer (`cardio:pubmed-37855029`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 19fce2a88bba781e92f8bbca3b3b5a342a3c44ebede83201be328fd31202c903
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
